Congo vs South Sudan: Average cost of multi drug-resistant tuberculosis treatment
Congo
726 constant 2022 US$
in 2024
South Sudan
682 constant 2022 US$
in 2024
Congo rank
66th
South Sudan rank
69th
Average cost of multi drug-resistant tuberculosis treatment over time
- Congo
- South Sudan
How they compare
Congo currently reports 726 constant 2022 US$ against 682 constant 2022 US$ in South Sudan, a difference of 44 constant 2022 US$.
That makes Congo's figure about 1.1 times South Sudan's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was South Sudan ahead.
Congo ranks 66th and South Sudan ranks 69th of 92 countries.
South Sudan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Congo | South Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 502 constant 2022 US$ | 1,678 constant 2022 US$ | 1,176 constant 2022 US$ | South Sudan |
| 2020s | 671.8 constant 2022 US$ | 2,265 constant 2022 US$ | 1,593 constant 2022 US$ | South Sudan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Congo or South Sudan?
- Congo, at 726 constant 2022 US$ against 682 constant 2022 US$ in South Sudan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Congo and South Sudan?
- 44 constant 2022 US$, with Congo ahead.
- How many years of comparable data are there for Congo and South Sudan?
- 6 years are reported by both, from 2019 to 2024.
- How do Congo and South Sudan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Congo ranks 66th and South Sudan ranks 69th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.